Bioidentical Hormone Replacement Therapy

Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps
SAN DIEGO, June 24, 2011 /PRNewswire/ — Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced data from a new analysis characterizing the effects of SYMLIN® (pramlintide acetate) injection in patients with type 1 diabetes who used insulin pumps during two previously completed clinical studies. The data, which will be presented during a poster presentation at the 71st Scientific Sessions …
Optimal Vitamin Dosages; Hormone Replacement Therapy Viewer Q & A

This entry was posted on Wednesday, June 9th, 2010 at 9:20 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.